Principal Investigator Scott Manalis
Co-investigator Ram Sasisekharan
Project Website http://www-mtl.mit.edu.ezproxy.canberra.edu.au/researchgroups/mems/docs/2007/BioChempage35.pdf
Heparin is a highly sulfated glycosaminoglycan that is used as an important clinical anticoagulant. Monitoring and control of the heparin level in a patient's blood during and after surgery is essential, but current clinical methods are limited to indirect and off-line assays. We have developed a silicon field-effect sensor for direct detection of heparin by its intrinsic negative charge. The sensor consists of a simple microfabricated electrolyte-insulator-silicon (EIS) structure encapsulated within microfluidic channels. As heparin-specific surface probes, we used the clinical heparin antagonist protamine or the physiological partner antithrombin III. The dose-response curves in 10% PBS revealed a detection limit of 0.001 U/ml, which is orders of magnitude lower than clinically relevant concentrations. We also detected heparin-based drugs, such as the low-molecular-weight heparin enoxaparin (Lovenox) and the synthetic pentasaccharide heparin analog fondaparinux (Arixtra), which cannot be monitored by the existing near-patient clinical methods. We demonstrated the specificity of the antithrombin III functionalized sensor for the physiologically active pentasaccharide sequence. As a validation, we showed correlation of our measurements to those from a colorimetric assay for heparin-mediated anti-Xa activity. These results demonstrate that silicon field-effect sensors could be used in the clinic for routine monitoring and maintenance of therapeutic levels of heparin and heparin-based drugs and in the laboratory for quantitation of total amount and specific epitopes of heparin and other glycosaminoglycans.